This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.
Bristol Myers' Applications for Opdivo-Yervoy Combo Accepted
by Zacks Equity Research
Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
by Zacks Equity Research
The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
Esperion's Cholesterol Drugs Receive Approval in Europe
by Zacks Equity Research
Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.
Immunomedics Up as Breast Cancer Drug Study Shows Efficacy
by Zacks Equity Research
Immunomedics (IMMU) soars as the phase III study on breast cancer drug shows efficacy and will be subsequently halted.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM
3 Stocks Immune to the Coronavirus Downturn to Buy Right Now
by Benjamin Rains
Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...
The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck
Top Stock Reports for J&J, Merck, Novartis & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Merck (MRK) and Novartis (NVS).
Merck (MRK) Stock Moves -0.81%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $76.25 in the latest trading session, marking a -0.81% move from the prior day.
Why Merck (MRK) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Seattle Genetics Issue Update on Padcev Label Expansion Study
by Zacks Equity Research
Seattle Genetics (SGEN) may receive an expedited approval pathway for Padcev combo to treat patients with locally advanced/metastatic urothelial cancer in the first-line setting in the United States.
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates
by Kinjel Shah
J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis
by Zacks Equity Research
Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.
Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy
by Benjamin Rains
Eli Lilly (LLY) stock closed the first quarter above where it started, which was no easy task. So let's dive into why investors might want to buy LLY stock right now...
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.
Pharma, Biotech Players Step Up Efforts Against Coronavirus
by Indrajit Bandyopadhyay
Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $68.22, marking a -1.2% move from the previous day.
Eiger Completes NDA Submission of Progeria Drug Lonafarnib
by Zacks Equity Research
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.
Lilly Gets CRL for Jardiance in Type I Diabetes Indication
by Zacks Equity Research
Lilly's (LLY) label expansion application seeking approval of its type II diabetes medicine as a treatment for type I diabetes fails to get approval from the FDA.
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
by Kinjel Shah
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.